Love Employee
- AbCellera Biologics (NASDAQ:ABCL) is up ~3% in Monday trading after announcing a collaboration with Biogen (NASDAQ:BIIB) to develop antibodies to treat neurological ailments.
- The agreement calls for the discovery of a novel target that would allow for the delivery of treatment through the blood brain barrier.
- Terms call for AbCellera (ABCL) to receive an undisclosed upfront payment as well as milestone payments. The company is also eligible to receive royalties on sales of therapies developed through the collaboration that make it to market.